KYMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kymera Therapeutics Inc (KYMR) is not an ideal buy for a beginner, long-term investor at this moment. While the company has strong analyst support and a promising pipeline, the recent insider selling, weak financial performance, and lack of significant positive trading signals suggest waiting for a better entry point.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 32.943, and the stock is trading near its support level of 83.299. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the overall technical indicators suggest caution.
Strong analyst support with multiple price target increases, including UBS ($128), Citi ($120), and Piper Sandler ($140).
Promising clinical data supporting its oral protein degraders.
Expanding market opportunities in type 2 diseases and immunology.
Insider selling has increased significantly by 238.41% over the last month.
Weak financial performance in Q4 2025, with revenue down 61.18% YoY and net income still negative.
Recent news of share dilution with plans to sell 200,000 shares for $18.27 million.
Wolfe Research downgrade citing valuation concerns and lack of catalysts.
In Q4 2025, revenue dropped by 61.18% YoY to $2.87 million. Net income improved slightly but remains negative at -$86.98 million. EPS increased to -0.97, up 10.23% YoY. Gross margin remains at 100%. Overall, financials show improvement in losses but weak revenue growth.
Analysts are generally bullish on KYMR, with multiple firms raising price targets recently. UBS raised its target to $128, Citi to $120, and Piper Sandler to $140, citing strong clinical data and market opportunities. However, Wolfe Research downgraded the stock due to valuation concerns and lack of near-term catalysts.
